Navigation Links
GenVec Reports Third Quarter 2011 Financial Results
Date:11/9/2011

th periods are primarily due to lower clinical costs as a result of the termination of the TNFerade clinical trial (PACT). 

GenVec ended the third quarter of 2011 with $28.5 million in cash, cash equivalents, and short-term investments.  "We anticipate revenues for 2011 will be between $18.0 million and $20.0 million. Based on our current level of activity, we currently project our cash burn to average approximately $2.0 million per quarter over the next 12 months," commented GenVec's Senior Vice President and Chief Financial Officer, Douglas J. Swirsky.

Webcast and Conference Call GenVec will hold a conference call today at 10:00 a.m. EST to discuss the Company's third quarter results. To listen to the live conference call, please dial 877-558-0567 (U.S. or Canada) or 706-643-4980 (international) and use Conference ID 23292607. An audio replay of the conference call will be available starting at 1 p.m. EST on November 9, 2011 through November 16, 2011. To listen to the audio replay, dial 855-859-2056 (U.S. or Canada) or 404-537-3406 (international) and use access code 23292607.

To access the webcast or the replay, go to www.genvec.com, click on "Investors and Media," and click on "Events and Presentations."

About GenVecGenVec is a biopharmaceutical company using differentiated, proprietary technologies to create superior therapeutics and vaccines. A key component of our strategy is to develop and commercialize our product candidates through collaborations. GenVec is working with leading companies and organizations such as Novartis, Merial, and the U.S. Government to support a portfolio of product programs that address the prevention and treatment of a number of significant human and animal health concerns. GenVec's development programs address therapeutic areas such as hearing loss and balance disorders; as well as vaccines against infectious diseases including respiratory syn
'/>"/>

SOURCE GenVec, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. GenVec to Release Third Quarter 2011 Financial Results and Conduct a Conference Call on November 9, 2011
2. GenVec to Present at Stifel Nicolaus 2011 Healthcare Conference
3. GenVec Reports Second Quarter 2011 Financial Results
4. GenVec Elects Adel A.F. Mahmoud and Edward M. Connor, Jr. to Board of Directors
5. GenVec to Host First Quarter 2011 Earnings Call and Webcast
6. GenVec Reports Fourth Quarter and 2010 Year-End Financial Results
7. GenVec Forms Collaboration With World-Leading Animal Health Company
8. GenVec Reports Third Quarter 2010 Financial Results
9. GenVec Receives Second-Year Funding From SAIC for HIV and Influenza Vaccine Development
10. GenVec Receives National Cancer Institute Grant to Expand Cancer Program
11. GenVec Announces Multiple Presentations at the American Society of Tropical Medicine and Hygiene Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)...  ArmaGen, Inc., a privately held biotechnology company ... neurological disorders, announced today that the first patient ... clinical trial of AGT-181 in patients with attenuated ... AGT-181 is an investigational enzyme replacement therapy (ERT) ... severe form of MPS I, Hurler syndrome, is ...
(Date:9/2/2015)... 2015  Aethlon Medical, Inc. (Nasdaq: AEMD ), today ... be presenting at the Rodman & Renshaw 17th Annual Global ... at 9:35 a.m. ET on Thursday, September 10, 2015. ... via live audio webcast which can be accessed by visiting ... http://www.aethlonmedical.com . The webcast will be archived for thirty ...
(Date:9/2/2015)... , Sept. 2, 2015  RegeneRx Biopharmaceuticals, Inc. ... drug development company focused on tissue protection, repair ... , President and Chief Executive Officer, will present ... Global Investment Conference, sponsored by H.C. Wainwright ... September 8-10, 2015 at the St. Regis Hotel ...
Breaking Medicine Technology:ArmaGen Announces First Patient Dosed in Phase 1/2a Clinical Trial of AGT-181 for the Treatment of Hurler Syndrome 2ArmaGen Announces First Patient Dosed in Phase 1/2a Clinical Trial of AGT-181 for the Treatment of Hurler Syndrome 3ArmaGen Announces First Patient Dosed in Phase 1/2a Clinical Trial of AGT-181 for the Treatment of Hurler Syndrome 4RegeneRx to Present at Rodman & Renshaw Global Investment Conference 2RegeneRx to Present at Rodman & Renshaw Global Investment Conference 3
(Date:9/2/2015)... Fredericksburg, VA (PRWEB) , ... September 02, 2015 ... ... integrator of document imaging, content, records and case management solutions and services to ... of PurePAGE®, its Image Re-sizing and Image Clean-up utility for IBM’s Datacap document ...
(Date:9/2/2015)... ... September 02, 2015 , ... On September 9, 2015, over 27,000 people from ... largest single-company convention to date for the state of Utah. , “We are thrilled ... event,” states David Stirling, doTERRA CEO. “One of the most exciting elements of our ...
(Date:9/2/2015)... ... ... “ G-Hold ” was featured on NewsWatch as part of its monthly Tech Report, ... technology expert and special reporter for NewsWatch, conducted the review and shared with viewers ... the likelihood of it dropping. , Tablets like the iPad and Samsung Galaxy Tab ...
(Date:9/2/2015)... ... 2015 , ... The payroll conference theme this year is ... covering legislative updates, including unemployment, global payroll best practices, and the latest trends ... Software, the American Payroll Association, Barnett Associates, and the IRS, will keep payroll ...
(Date:9/2/2015)... ... September 02, 2015 , ... Pentec Health, Inc., a national leader ... for an impressive sixth consecutive year. Less than 5 % of this year’s 5000 ... the “health” sector. Pentec’s 3-year revenue growth rate of 65% sustained its most ...
Breaking Medicine News(10 mins):Health News:EDAC Systems, Inc. announces a new version of its Image Enhancement and Image Re-Sizing utility EDAC’s PurePAGE® 2Health News:EDAC Systems, Inc. announces a new version of its Image Enhancement and Image Re-Sizing utility EDAC’s PurePAGE® 3Health News:doTERRA to Host the Largest Single-Company Convention in the State of Utah 2Health News:Comfortably Hold a Tablet with G-Hold Hands Free Tablet Holder 2Health News:23rd Annual NJ Statewide Payroll Conference in Vernon, NJ at the Minerals Hotel on October 15-16, 2015 2Health News:Pentec Health Once Again Named One of the Fastest-Growing Private Companies in America 2
... If the man who mowed down 32 persons at Virginia Tech ... you call the man who has devised a computer game ... rampage, players control an image of Korean-born gunman Cho Seung-hui. Screams ... the other characters. ,21-year-old Ryan Lambourn, an Australian, ...
... reward the federal government with their vote at the next ... the same time he concedes that two bad post-budget polls ... ,"I'm confident that come Election Day, people will reward ... Abbott was quoted. He said he was confident voters had ...
... extended time are the most common but contentious accommodation ... and/or AD/HD taking college entrance and licensing exams. According ... Practice, students given extra time respond to exams similarly ... ,According to my research, there is no real evidence ...
... Director-General of the World Health Organization, has called upon all member ... that would handicap the organization in the fight contain bird blu. ... . I would fail you," said he said in a speech ... countries, Chan said that "you are tying my hands, you're muffling ...
... past, the newborns umbilical cord was not clamped right ... naturally. This practice , known as late clamping, was ... immediately after the infant is expelled. However, this new ... studies on the importance of when clamping should be ...
... on animals, conducted by the National Toxicology Program (NTP), ... as hexavalent chromium (chromium 6) causes cancer when ... ,Hexavalent chromium compounds are often used in electroplating, leather ... some drinking water sources. ,The two-year study ...
Cached Medicine News:Health News:Australian Devises Online Game Based on Virginia Tech Shootout 2Health News:Tony Abbott Confident Of Australias Vote For Performance Not Promise 2Health News:WHO Director Urges Nations to Share Bird Flu Virus Strains 2Health News:Late Clamping of Umbilical Cord may Reduce Anemia in Children 2Health News:Late Clamping of Umbilical Cord may Reduce Anemia in Children 3
Coat-A-Count PAP IRMA,is an immunoradiometric assay designed,for the quantitative measurement of,prostatic acid phosphatase (PAP) in,serum. It is intended strictly for in vitro,diagnostic u...
For in vitro diagnostic use,with the IMMULITE 2000 Analyzer for,the quantitative measurement of prostatic,acid phosphatase (PAP) in serum, as an,aid in patient management....
Abbott offers an array of both in-vitro and molecular diagnostic tests for the detection and monitoring of cancerous conditions in patients....
For the quantitative measurement of human prostatic acid phosphatase (PAP) in human serum....
Medicine Products: